Search

Ultragenyx Pharmaceutical Inc

Затворен

СекторЗдравеопазване

25.61 2.93

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

24.65

Максимум

25.57

Ключови измерители

By Trading Economics

Приходи

93M

-92M

Продажби

78M

214M

EPS

-0.9

Марж на печалбата

-42.991

Служители

1,371

EBITDA

94M

-61M

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+121.42% upside

Дивиденти

By Acuity

Следващи печалби

3.11.2026 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

72M

2.5B

Предишно отваряне

22.68

Предишно затваряне

25.61

Настроения в новините

By Acuity

50%

50%

145 / 340 Класиране в Healthcare

Ultragenyx Pharmaceutical Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

31.08.2026 г., 21:02 ч. UTC

Ultragenyx Pharmaceutical Inc shares are lower in after-market hours, with no specific news identified. Broader market sentiment remains cautious amid Fed rate hike concerns.

28.08.2026 г., 22:56 ч. UTC

Ultragenyx Pharmaceutical Inc. shares are higher in after-market trading, though they remain below their 20-day moving average after recent declines.

26.08.2026 г., 20:08 ч. UTC

News

Ultragenyx Pharmaceutical granted 45,984 restricted stock units to new non-executive officers as part of its Employment Inducement Plan. Shares are trading roughly flat.

25.08.2026 г., 23:16 ч. UTC

News

Ultragenyx Pharmaceutical granted nearly 46,000 restricted stock units to new hires, boosting shares in after-market trading amid ongoing strategic initiatives for rare diseases.

24.08.2026 г., 23:16 ч. UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, reflecting a modest increase since Monday's close amid no specific news to explain the movement.

22.08.2026 г., 00:02 ч. UTC

Ultragenyx Pharmaceutical shares are lower in after-market hours, with no specific news identified. The broader market has shown notable gains.

21.08.2026 г., 23:11 ч. UTC

Ultragenyx Pharmaceutical shares moved higher in after-market trading, reflecting broader market gains despite the absence of specific company news.

20.08.2026 г., 23:46 ч. UTC

Ultragenyx Pharmaceutical Inc. shares are higher in after-market trading, showing modest gains since Thursday's close, despite no specific news identified.

19.08.2026 г., 23:51 ч. UTC

News
Social Media

Ultragenyx Pharmaceutical received FDA accelerated approval for its gene therapy GENGLYCOS, leading shares to rise sharply in after-market hours.

18.08.2026 г., 23:26 ч. UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market hours. No specific news was identified to explain the price movement.

17.08.2026 г., 23:51 ч. UTC

Ultragenyx Pharmaceutical Inc shares rose in after-market trading, gaining traction despite broader market volatility from geopolitical tensions and rising crude oil prices.

15.08.2026 г., 00:06 ч. UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, reaching a high of 2.96% following Friday's close amid broader economic concerns.

14.08.2026 г., 22:51 ч. UTC

Ultragenyx Pharmaceutical Inc shares rose in after-market trading, advancing significantly since Friday's close amid easing expectations for Federal Reserve interest rate hikes.

13.08.2026 г., 19:16 ч. UTC

Correlated Moves

Ultragenyx Pharmaceutical Inc. is declining, reflecting broader biotech sector weakness and a noted correlation with LABU's significant downturn.

12.08.2026 г., 22:16 ч. UTC

Ultragenyx Pharmaceutical shares are higher in after-market trading, reflecting positive price movement amid a stable monetary policy outlook and recent inflation data.

11.08.2026 г., 19:36 ч. UTC

News

Ultragenyx Pharmaceutical reached a settlement with Esjay Pharma over DOJOLVI patent litigation, allowing a generic version to launch in 2023. Shares are higher today.

10.08.2026 г., 19:16 ч. UTC

News

HC Wainwright reiterated its Buy rating on Ultragenyx Pharmaceutical, maintaining a $50 price target, contributing to shares trading higher during the session.

7.08.2026 г., 20:03 ч. UTC

News

Ultragenyx Pharmaceutical reported a loss of -$0.90 per share, beating estimates. Revenue of $214 million also exceeded expectations, but shares are trading roughly flat.

6.08.2026 г., 23:21 ч. UTC

Ultragenyx Pharmaceutical Inc shares are higher in after-market trading, showing unusual strength despite remaining below their 20-day moving average.

5.08.2026 г., 19:52 ч. UTC

News

Ultragenyx shares are lower after Wells Fargo cut its price target to $45. The company reported an EPS loss of $0.90, exceeding expectations.

4.08.2026 г., 23:02 ч. UTC

News

Ultragenyx Pharmaceutical reported second-quarter revenue of $214 million and narrowed its net loss to $92 million, with shares trading higher in after-market hours.

3.08.2026 г., 22:51 ч. UTC

Ultragenyx Pharmaceutical shares are trading roughly flat after-market. The stock is down significantly compared to its month-ago close and below its 20-day moving average.

31.07.2026 г., 19:52 ч. UTC

Correlated Moves

Ultragenyx Pharmaceutical is lower today amid a decline in the Biotechnology sub-sector, with shares near the lower end of their one-month range.

30.07.2026 г., 19:58 ч. UTC

Correlated Moves

Ultragenyx rises, supported by SPDR S&P Biotech ETF gains.

29.07.2026 г., 18:43 ч. UTC

Ultragenyx Pharmaceutical is lower today, continuing a decline amid broader market pressures from rising crude oil prices and geopolitical tensions.

28.07.2026 г., 19:03 ч. UTC

Ultragenyx Pharmaceutical Inc shares are trading lower, reflecting a challenging performance backdrop amid strength in U.S. mega-cap stocks. No specific news was identified.

27.07.2026 г., 19:07 ч. UTC

Ultragenyx Pharmaceutical Inc shares are higher as crude oil prices decline, easing geopolitical concerns. No specific company news was identified for the move.

24.07.2026 г., 19:51 ч. UTC

Ultragenyx Pharmaceutical Inc shares are declining, continuing a trend of lower daily closes. Broader market volatility and new tariffs may be contributing factors.

22.07.2026 г., 19:36 ч. UTC

Ultragenyx Pharmaceutical shares are declining amid rising crude oil prices due to U.S.-Iran tensions. The stock remains below its 20-day moving average.

21.07.2026 г., 19:22 ч. UTC

Correlated Moves

Rising amid broader market gains and SPDR S&P Biotech support.

Сравнение с други в отрасъла

Ценова промяна

Ultragenyx Pharmaceutical Inc Прогноза

Ценова цел

By TipRanks

121.42% нагоре

12-месечна прогноза

Среден 55.82 USD  121.42%

Висок 103 USD

Нисък 28 USD

Според 18 анализатори от Wall Street, предложили 12-месечна ценова цел за Ultragenyx Pharmaceutical Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

18 ratings

16

Купи

2

Задържане

0

Продай

Настроение

By Acuity

145 / 340 Класиране в Здравеопазване

Настроения в новините

Neutral

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Ultragenyx Pharmaceutical Inc

Ultragenyx Pharmaceutical Inc., a biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of novel products for the treatment of rare and ultra-rare genetic diseases in North America, Latin America, Japan, Europe, and internationally. Its biologic products include Crysvita (burosumab), an antibody targeting fibroblast growth factor 23 for the treatment of X-linked hypophosphatemia, as well as tumor-induced osteomalacia; Mepsevii, an enzyme replacement therapy for the treatment of children and adults with Mucopolysaccharidosis VII; Dojolvi for treating long-chain fatty acid oxidation disorders; and Evkeeza (evinacumab) for the treatment of homozygous familial hypercholesterolemia. The company's products candidatures include DTX401, an adeno-associated virus 8 (AAV8) gene therapy clinical candidate for the treatment of patients with glycogen storage disease type Ia; DTX301, an AAV8 gene therapy for the treatment of patients with ornithine transcarbamylase; UX143, a human monoclonal antibody for the treatment of osteogenesis imperfecta; GTX-102, an antisense oligonucleotide for the treatment of Angelman syndrome; UX111, an AAV9 gene therapy product candidate for the treatment of patients with Sanfilippo syndrome type A, or MPS IIIA, a rare lysosomal storage disease; UX701, for the treatment of Wilson disease; and UX053 for the treatment of glycogen storage disease type III. Ultragenyx Pharmaceutical Inc. has collaboration and license agreement with Kyowa Kirin Co., Ltd.; Saint Louis University; Baylor Research Institute; REGENXBIO Inc.; Bayer Healthcare LLC; GeneTx; Mereo; University of Pennsylvania; Arcturus Therapeutics Holdings Inc.; Solid Biosciences Inc.; Regeneron; Abeona; and Daiichi Sankyo Co., Ltd. The company was incorporated in 2010 and is headquartered in Novato, California.
help-icon Live chat